Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does MEPOLIZUMAB Cause Malignant neoplasm progression? 5 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Malignant neoplasm progression have been filed in association with MEPOLIZUMAB (Nucala). This represents 0.0% of all adverse event reports for MEPOLIZUMAB.

5
Reports of Malignant neoplasm progression with MEPOLIZUMAB
0.0%
of all MEPOLIZUMAB reports
4
Deaths
3
Hospitalizations

How Dangerous Is Malignant neoplasm progression From MEPOLIZUMAB?

Of the 5 reports, 4 (80.0%) resulted in death, 3 (60.0%) required hospitalization, and 3 (60.0%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for MEPOLIZUMAB. However, 5 reports have been filed with the FAERS database.

What Other Side Effects Does MEPOLIZUMAB Cause?

Asthma (11,033) Dyspnoea (9,192) Wheezing (6,093) Product dose omission issue (5,873) Cough (4,577) Pneumonia (4,107) Therapeutic product effect incomplete (4,106) Drug ineffective (3,880) Loss of personal independence in daily activities (3,566) Fatigue (2,656)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which MEPOLIZUMAB Alternatives Have Lower Malignant neoplasm progression Risk?

MEPOLIZUMAB vs MEPROBAMATE MEPOLIZUMAB vs MERCAPTOPURINE MEPOLIZUMAB vs MEROPENEM MEPOLIZUMAB vs MEROPENEM ANHYDROUS MEPOLIZUMAB vs MESALAMINE

Related Pages

MEPOLIZUMAB Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression MEPOLIZUMAB Demographics